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Background and aims: While it is commonly accepted that Inflammatory bowel disease (IBD)
Comprehensive Care Units (ICCUs) facilitate the delivery of quality care to Crohn's disease and
ulcerative colitis patients, it remains unclear how an ICCU should be defined or evaluated. The
aim of the present study was to develop a comprehensive set of Quality Indicators (QIs) of
structure, process, and outcomes for defining and evaluating an ICCU.
Methods: A Delphi consensus-based approach with a standardized three-step process was used
to identify a core set of QIs. The process included an exhaustive search using complementary
approaches to identify potential QIs, and two Delphi voting rounds to select the QIs defining the
core requirements for an ICCU.
Results: The consensus selected a core set of 56 QIs (12 structure, 20 process and 24 outcome).
Structure and process QIs highlighted the need for multidisciplinary management and continuity
of care. The minimal IBD team should include an IBD nurse, gastroenterologists, radiologists,
surgeons, endoscopists and stoma management specialists. ICCUs should be able to provide both
outpatient and inpatient care and admission should not break the continuity of care. Outcome
QIs focused on the adequate prophylaxis of disease complication and drug adverse events, the
need to monitor appropriateness of treatment and the need to reinforce patient autonomy by
providing adequate information and facilitating the patients' participation in their own care.
Conclusions: The present Delphi consensus identified a set of core QIs that may be useful for
evaluating and certifying ICCUs.
© 2013 The Authors. Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.
Open access under CC BY-NC-ND license.1. Introduction
Crohn's disease (CD) and ulcerative colitis (UC) have a
substantial impact on patients' physical health, social func-
tioning and quality of life1,2. Optimal care for these patients
attains remission, avoids disease and treatment-related
complications and allows patients with inflammatory bowel
disease (IBD) to achieve normal social functioning and quality
of life3. This care requires the coordinated action of a number
of health care professionals who are members of functional
IBD Comprehensive Care Units (ICCUs).
Although the available guidelines provide support for the
management of IBD4–12, they do not cover all factors that need
to be integrated to provide the best care. Aspects like a
multidisciplinary approach, or the processes and structurethat are required for optimal patient care, are often not
considered but may be as important as the availability and
proper use of effective medicines. Furthermore, it has been
shown that expert management can decrease morbidity,
surgery requirement, and even mortality in patients with
IBD13–16. While it is commonly accepted that ICCUs facilitate
the provision of quality care to CD and UC patients, it
remains unclear how an ICCU should be defined. Specifically,
the minimal requirements that a unit should fulfill to be
categorized as an ICCU, the basic tasks and procedures that
an ICCU should perform or how to measure its functioning,
have not been established. A systematically developed set of
structure, process and outcome Quality Indicators (QIs) is
fundamental for certifying ICCUs, evaluating their quality, and
identifying areas for improvement.
Figure 1 Flow-chart of the Quality Indicators (QI) selection
process.
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ICCUs10–12,16–30 have evaluated individual aspects of care,
specifically the delivery of on demand therapy or multidis-
ciplinary care. Only a few have provided a defined set of QIs
or characteristics that may help to categorize and evaluate a
unit of this kind. To be useful, QIs should comply with the
following minimal series of requirements: a) all stakeholders
should be involved in their definition, b) they should be
measurable for future evaluation, c) QI requirements should
be reasonably achievable by currently active ICCUs and
d) the best methodology available should be used to select
the most important QI. A major limitation of currently
published QIs is the lack of a clear methodology for system-
atically detecting, evaluating and selecting variables.
The current best options for selecting QIs are probably the
methods using Delphi consensus agreements. The Delphi
process is particularly suitable when views of different fields
(in this case nurses, patients and physicians) have to be
integrated31. The Delphi panel approaches combine a system-
atic review of the literature for the best available scientific
data with an iterative process to obtain the collective
judgment of experts in order to determine the appropriate-
ness of processes of care in medicine. This approach is now
widely used to develop QI across all areas of medicine32–34.
This method of selecting QIs is reliable and has been shown to
have content, construct, and predictive validities35.
Few studies in gastroenterology have developed explicit
QIs using Delphi consensus36,37, and, to our knowledge, this
approach has only recently been used in the area of IBD38.
The aim of the present study was to develop a comprehen-
sive set of structure, process, and outcome QIs for defining
and evaluating an ICCU, based on expert consensus using a
Delphi consensus method.
2. Materials and methods
We used a Delphi consensus-based approach with a standard-
ized three-step process to identify a set of QIs, as described
below (Fig. 1). The method uses a formal group process, in
which an expert panel discusses and iteratively rates the
appropriateness of candidateQIs using a two-roundweb-based
survey31,39.
2.1. Development of Quality Indicators
An exhaustive search applying three different and comple-
mentary approaches was used to identify potential QIs:
a) Literature search. An extensive search was performed in
EMBASE, MEDLINE, the Indice Médico Español, MEDES-MED,
and The Cochrane Plus Library using multiple search strategies
(annex 1). In addition, a generic search in Google and multiple
searches in government and non-governmental institutions for
“grey literature” were performed. QIs obtained from the
documents retrieved in the literature search were collected
and added to the initial comprehensive list of potential QIs.
b) Existing clinical guidelines4–12 were reviewed to estab-
lish an ordered set of candidate QIs for subsequent evaluation.
c) Discussion groups: Three separate discussion groups
were created comprising patients, nurses, and medical
doctors respectively. The groups had from eight to ten
participants and were designed to represent the respectivepopulations — for example, regarding the proportion of CD or
UC, or sex distribution for patients. IBD-dedicated nurses
and doctors were recruited to represent different hospital
levels and geographical areas of Spain. If the proposed
structure, process and outcome QIs did not appear sponta-
neously in conversation the trained investigator mentioned
it explicitly. The discussions were recorded and transcribed,
and the content was further analyzed in order to identify
possible QI using the NUDIST Vivo 8 program.
The QIs were initially categorized according to the process
of care (prophylaxis, diagnosis, treatment, etc.) that they
covered. For each candidate QIs, the population to which it
applied and the process of care that it measured were
defined. Specifically, candidate QIs are designed using “if
and then” statements, where “if” describes the eligible
patient population and “then” defines the process of care
that should be performed. For example: “If a patient has been
diagnosed of IBD, then s/he should be tested for markers of
hepatitis B virus and inoculatedwith vaccinewhen indicated”.
The scientific committee (SC) included five medical
doctors with IBD expertise, one nurse, and one patients'
representative. All were designated by and acted in repre-
sentation of their respective national societies. The SC
included also two support methodologists. During the prepa-
ration of the QIs, six members of the SC – one patient, one
nurse, and four gastroenterologists – evaluated the initial
set of QIs for five major characteristics: straightforward
identification in medical records (i.e., availability, ease of
data retrieval, and cost), the number of indicators developed
(with regard to an optimal number), evidence in the
literature, structure versus process indicators, and linkage to
outcomes (i.e., the need to demonstrate that adherence to
indicators is associated with better outcomes)36. Redundant
243Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsQIs and those not fulfilling these characteristics were
eliminated to keep the number of QIs to be voted on by the
participants within reasonable limits.
2.2. Selection of expert panel members
The expert panel members were selected by the SC and
included patient representatives (n = 4), nurses (n = 7),
surgeons (n = 2) and physicians (n = 18). Most members of the
SC also participated in the voting process. The predominance
of gastroenterologists and nurses was justified by the need that
participants should have previous knowledge and extensive
experience of the structure and functioning of ICCUs. In this
regard, nurse and physician panelists were selected because
they were well-known experts in IBD and all of them had
published studies in the area of IBD in peer-reviewed journals.
All participants had also preferential dedication to IBD and lead
or work in either dedicated IBD clinics or ICCUs. In addition,
many of the panel members were selected due to their
responsibilities in management or their expertise in Delphi
consensus. Medical and nurse panelists represented hospitals
that differed markedly in size, complexity, and geographical
location within Spain.
2.3. Expert panel ratings
Overview: As stated below, a Delphi method was used to rate
the appropriateness of each candidate QI. In the first round,
the experts rated each proposed QI individually without
interaction with other members. Ratings were based on theTable 1 Scoring of core structure Quality Indicators.
Quality indicators
Hospital characteristics
1. The ICCU should have a dedicated outpatient clinic with nurse c
2. The ICCU should have outpatient facilities where drugs can be
administered intravenously.
3. The ICCU should be integrated in a hospital with an Emergency De
4. The ICCU should be integrated in a Digestive Disease Departmen
has hospitalization facilities.
5. The ICCU should be integrated in a hospital with an Endoscopy U
Specific ICCU facilities
6. There should be outpatient specialized clinics for IBD patients.
7. The ICCU should have a telephone service for patient consultati
Registers
8. The ICCU should have a registry of all the IBD patients.
9. The ICCU should have a registry of IBD patients receiving biologic
Personnel
10. The ICCU should have at least one IBD specialized nurse.
Personnel: Referral professionals
11. The ICCU should include a surgeon or surgical team with exper
in the surgical treatment of IBD patients.
12. The ICCU should include a reference radiologist with experienc
digestive diseases.review of an evidence report distributed to the panel in
advance. These ratings were analyzed in order to assess their
relative relevance, removing the less significant QI and adding
new ones following the panelists' suggestions. In the second
round the panelists were allowed to vote, without suggesting
modifications or adding comments. Each of the indicators
was then re-rated in an iterative process. Reaching agreement
was not required during the panel rating process. Voting
was anonymous and the votes of all panelists had the same
weight in the analysis. In addition, according to their field of
expertise, nurse and patient participants were allowed to
waive a question when they considered that they were unable
to provide an informed answer.2.4. Rating system
Before the first round of ratings, the panel was provided
with an e-mailed report summarizing the literature review,
the topics considered in the discussion groups, and the list of
candidate QIs. Using the best available data contained in the
report, the panelists rated the relevance of each candidate QI
using a standard nine-point scale where 1 indicates “extremely
irrelevant” and 9 indicates “extremely relevant”. They were
also tasked with identifying additional QIs not included on
the original list, or modifying existing QIs that were deemed
to be imperfect. The mean of the panel ratings and a measure
of dispersion for each indicator were determined. Agreement
was evaluated using the coefficient of variation (CV) from very
high (CV b 25%), high (25%–50%) or low (N50%–75%) to very
low (N75%).Number of
panelists
answering
Overall
score
Physicians'
score
Nurses'
score
Patients'
score
are. 31 8 7.7 8.7 8.3
31 8.4 8.5 8.4 8.0
partment. 31 8.2 8.2 8.3 8
t that 31 8.6 8.7 8.6 8.5
nit. 31 8.4 8.5 8.4 8
31 8 8.1 7.4 8.8
on. 31 8.1 7.9 8.7 8.3
31 8.3 8.3 8.6 7.5
al drugs. 31 8.1 8.2 7.6 8.5
31 8 7.7 8.6 8.5
ience 31 8.5 8.6 8.4 8.5
e in 31 7.8 7.9 8 7.3
Table 2 Scoring of core process Quality Indicators.
Quality Indicators Number of
panelists
answering
Overall
score
Physicians'
score
Nurses'
score
Patients'
score
Quality and organization
13. The ICCU should offer the possibility of urgent outpatient
consultation when there is a presumption of flare or
complication. On demand care
should be available at least from Monday to Friday.
31 8.4 8.2 8.6 8.8
14. The ICCU should have a preferential visit circuit for patients
sent by their GP, the emergency ward or other health care
professionals for a recent diagnosis or a severe flare of IBD.
31 7.9 7.9 7.5 8.8
15. Each IBD patient should be assigned an identifiable IBD
specialist in charge of his/her clinical care.
31 7.1 6.7 7.1 9
Diagnostic tests
16. The ICCU should have access to CT. 31 8.5 8.5 8.4 8.8
17. The ICCU should have access to MRI. 31 8.5 8.4 8.4 8.8
18. The ICCU should have access to abdominal ultrasound. 31 8.3 8.2 8.3 8.8
Patient care
19. The ICCU should have access to therapeutic endoscopic
dilation of bowel strictures.
31 8.1 8.1 8.3 8.3
20. The ICCU should have a clinical and laboratory monitoring
program for patients under immunosuppressive treatment.
31 8.7 8.7 8.7 8.8
Patient care
21. The ICCU should have a clinical and analytical monitoring
program for patients under biological treatments.
31 8.7 8.7 8.7 8.8
22. The patient should receive a card with the contact data of the
IBD unit, including the telephone number and opening hours.
31 8.2 8 8.4 8.5
23. The ICCU should have a colorectal cancer surveillance program
in IBD patients, in line with international guidelines.
27 7.9 7.7 8.3 –
24. Complex care decisions, including surgery indication, should be
discussed in IBD committees including a gastroenterologist,
a radiologist and a surgeon.
29 8.2 8.2 8 9
Surgery
25. Elective surgery should be performed exclusively by
surgeons from the ICCU.
30 7.9 8.2 6.8 8
26. Before surgery that may result in a temporary or permanent
stoma, the IBD patient should have an appointment with a
nurse specialized in stoma care.
31 8.1 8 8.1 8.3
Admission
27. The ICCU gastroenterologist should actively participate in the
management of the hospitalized IBD patient.
31 8.4 8.5 8.1 8.8
Guidelines
28. The ICCU should maintain their own updated protocols or
adhere to international guidelines on the management of IBD.
27 8.3 8.5 8 8.8
29. The ICCU should have protocols for the use of drugs. 30 8.1 8 7.9 9
30. The ICCU should have a specific protocol for IBD patients
admitted to the Emergency Department; emergency
department staff should have full access to this protocol.
30 7.3 7.3 6.9 9
Continuing education and research
31. Gastroenterologists in the ICCU should participate in at
least one educational activity about IBD per year.
24 8 8 7.8 –
32. The ICCU should carry out and/or participate in research
projects on IBD.
29 8 8 8.1 8.3
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245Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsThe SC predefined a cut-off value of 7.5 for
structure, process and outcome items to be included
as QIs. To explore the potential different perspectives
of physicians, patients and nurses, a predefined separate
subgroup analysis of responses was performed in additionTable 3 Scoring of core outcome Quality Indicators.
Quality Indicators
Diagnosis and follow-up
33. When a patient is diagnosed with IBD, s/he should undergo a
thorough study of the extension of disease, including colonosc
and a small bowel assessment if there is a suspicion of CD.
34. Before starting treatment with a biologic drug, IBD patients sh
be tested for tuberculosis using either two consecutive tuberc
tests or an immunologic test and a chest X-ray.
35. IBD patients should be tested for hepatitis B and C at diagnosis
36. All IBD patients should be vaccinated against Hepatitis B.
37. In patients with UC and a severe flare, rectal biopsies should b
taken to rule out Cytomegalovirus infection.
Treatment
38. Before starting treatment with a biologic drug, IBD patients w
sign of tuberculosis (on chest X-rays, or on tuberculin or immu
tests) should receive adequate antituberculous therapy.
39. All HBsAg-positive IBD patients should receive antiviral drugs w
being treated with an anti-TNF drug.
Treatment
40. Attenuated virus vaccines must be avoided in patients receivin
immunosuppressive or anti-TNF drugs.
41. IBD patients with suspected septic complications should receiv
early appropriate antibiotic treatment.
42. In all IBD patients who had required two or more courses of ste
in the last year, treatment with an immunosuppressive drug sh
have been considered.
43. In patients with severe flare of UC not responding to intraveno
steroids, treatment with either cyclosporine or an anti-TNF dr
should be initiated within 7 days.
44. Patients with steroid-refractory CD should receive an anti-TNF
45. No IBD patients should receive a steroid dose over 20 mg a day
more than 6 months.
46. Antithrombotic therapy should be indicated in all IBD patients
hospitalized.
47. IBD patients should maintain thiopurine treatment during preg
Refusal of treatment should be documented.
Treatment
48. It should be documented in the clinical records that patient re
adequate information regarding benefits and risks before bein
started on immunosuppressive therapy.
49. It should be documented in the clinical records that patients r
adequate information regarding benefits and risks before start
biologic therapy.
50. Patients receiving immunosuppressive drugs should be monitor
with a blood count at least every four months.to the general Delphi analysis. QIs not meeting criteria
for selection in the whole group but rated 9 over 9 by any
of the groups – physicians, nurses or patients – were
assessed individually and included in the final set of
indicators.Number of
panelists
answering
Overall
score
Physicians'
score
Nurses'
score
Patients'
score
opy
31 8.1 8.3 8.1 6.8
ould
ulin
27 8.9 8.9 9 –
. 27 8 8 8 –
28 7.9 8 7.8 –
e 25 8.6 8.5 9 –
ith any
nologic
30 8.8 8.8 9 8
hile 20 8.7 8.7 – –
g 26 8.7 8.7 8.7 –
e 25 8.6 8.7 8.6 –
roids
ould
25 8.6 8.6 8.8
us
ug
20 8.6 8.6
agent. 24 8.1 8 8.3 –
for 20 8.1 8.1 – –
while 24 8 8.3 7.3 –
nancy. 25 8.2 8.3 7.6 –
ceived
g
28 8 8 8 8,3
eceived
ing
28 8.1 8 8.2 8.3
ed 29 8.1 7.9 8.8 8.3
26 8.1 7.8 8.7 –
(continued on next page)
Table 3 (continued)
Quality Indicators Number of
panelists
answering
Overall
score
Physicians'
score
Nurses'
score
Patients'
score
51. Patients receiving anti-TNF drugs should be monitored with a blood
count at least every four months.
Surgery
52. In IBD patients undergoing elective surgery, rates of severe morbidity
requiring ICU admission should be lower than 5%.
20 8.2 8.2 – –
53. Mortality of elective surgery should be less than 2%. 20 8.2 – –
54. Ileo-anal pouches should only be made by surgeons performing at least
10 of these operations a year.
20 – 8 – –
55. It should be documented in the clinical records that the patient
has received adequate information regarding benefits and risks
before surgery.
23 8 8 8 –
Surgery
56. Rates of temporary ileostomy after elective ileocecal resection
should be lower than 20%.
22 8 8 – –
246 X. Calvet et al.As many QIs scored above this cut-off point, the value
was increased post-hoc to keep the number of QIs within
reasonable limits. These were named “core QI”, always
selecting the higher ratings. The remaining QIs with scores
above the pre-established 7.5 cut-off are provided in a
table.
3. Results
3.1. Selection of QI and Delphi rounds
After the literature review and synthesis, discussions groups
and the review of the guidelines, 503 potential QIs were
identified (Fig. 1). To reduce this set to a manageable size,
two members of the SC and one supporting methodologist
reviewed the QIs and eliminated duplicated or clearly
inadequate items. In addition, the health professionals of
the SC and the members of the physician discussion group
evaluated the remaining set of items for their relevance
from 1 to 9 on a Likert scale. QIs that did not reach a minimal
score of 5 were eliminated. A final set of 126 QIs, comprising
40 structure, 44 process and 42 outcome QIs, were included
in the first Delphi round.
After receiving the panelists' votes and the comments, the
SC modified the wording of many QIs, introducing substantial
changes in some cases. The second Delphi round also included
126 QIs — again, 40 structure, 44 process and 42 outcome.3.2. Analysis and selection of the final set of QIs
After the second Delphi round, 83 QIs scored over 7.5 out of
9 and reached good or very good agreement between the
panelists. As the number of QIs above the predefined cut-off
point of 7.5 was high, the SC decided to establish a core
set of 56 QIs (12 structure, 20 process and 24 outcome). Core
QIs were selected including the highest rated QIs and the
QIs voted 9/9 by any of the major participant groups
(physicians, nurses or patients).3.3. Description of selected QIs
Core QIs are shown in Tables 1 to 3 and additional selected QIs
in Table 4. The two main principles underlying the structure
and process QIs were the need for multidisciplinary manage-
ment and the continuity of care. Regarding multidisciplinary
management, physicians, nurses and patients perceived the
role of the IBD nurse as an essential part of IBD patient care.
Core QIs include the need for a nurse and time and space for
specific nurse outpatient consultations. In addition to nurses
and gastroenterologists, the minimal IBD team should include
radiologists, surgeons and endoscopists. Another component
considered essential was support from a nurse specialized
in stoma management. The QIs also underline the need to
provide care in a hospital environment equipped with an
Emergency Department, inpatient facilities and an essential
set of radiological and endoscopic examinations.
All stakeholders also agreed on the importance of the
continuity of care and on demand care: that is, ICCUs should
be able to provide both outpatient and inpatient care.
Outpatient care should include the possibility of drug
infusion, monitoring of patients under immunosuppressive
and biologic drugs, and availability of on demand outpatient
consultation, including over-the-phone consultation. Ad-
mission should not break the continuity of care: the same
team should provide outpatient care, prescribe, administer
and monitor the treatment, and provide inpatient care.
Regarding the process QIs, patients were especially con-
cerned about two specific points: having a protocol for their
management when admitted to the Emergency Department
and being assigned to a named, specific IBD specialist
responsible for their care.
Outcome QIs can be divided in three main groups. The
first group refers to the adequate prophylaxis of disease
complications and drug adverse events — for example,
tuberculosis screening and prophylaxis in patients taking
biologics, or the need to prevent CD recurrence after
surgery. The second group relates to the need of monitoring
the appropriateness of treatment — for example, the
indication of biologics in steroid-refractory IBD. Finally,
247Quality indicators for Inflammatory Bowel Disease Comprehensive Care Unitsthe third group comprises a large number of QIs highlighting
the need to reinforce patient autonomy by providing
adequate information, allowing patients to take their own
informed decisions and facilitating their participation in
their own care.Table 4 Selected additional Quality Indicators.
Quality Indicators
Structure Quality Indicators
57. The ICCU should have the infrastructure to allow on demand a
the patients who develop symptoms between scheduled visits.
58. The ICCU should have the infrastructure to allow patients to c
professionals about their disease or its treatment between sch
visits.
Structure: Hospital characteristics
59. The ICCU should be integrated in a hospital with a Department
60. The ICCU should be integrated in a hospital with a Radiology D
Structure: Specific ICCU facilities
61. The ICCU should have examination rooms for appointments wit
physicians.
62. The ICCU should have a telephone hotline for patient consulta
during specified hours at least on working days.
63. The IBD should have examination rooms for appointments with
Structure: Registers
64. The ICCU should have a registry of the IBD patients receiving
immunosuppressive therapy.
Structure: Personnel
65. The ICCU should have at least two IBD specialized gastroentero
Structure: Personnel organization
66. The ICCU should have an identifiable person in charge.
Structure: Personnel: Reference professionals
67. The ICCU should receive support from a nurse specialized in st
68. The ICCU should receive support from endoscopists with traini
endoscopic therapy in IBD patients.
Process Quality Indicators
Process: Diagnostic test
69. The ICCU should have access to endoanal ultrasonography.
Process: Guidelines
70. Protocols should be revised at least once each 4 years.
Process: Continuing education
71. Nurses in the ICCU should participate in at least one educati
activity on IBD per year.
72. Surgeons in the ICCU should participate in at least one educ
activity on IBD per year.
Process: Research and committees
73. The ICCU should offer patients who do not respond to approved
treatments the possibility of participating in clinical trials,
whether in the same ICCU or in another ICCU with research infr
74. All patient deaths should be discussed by mortality committ4. Discussion
In any field of medicine, Quality Indicators are needed to
monitor patient management. Our study provides a compre-
hensive set of QIs for defining and evaluating ICCUs obtainedNumber
of
panelists
answering
Overall
score
Physicians'
score
Nurses'
score
Patients'
score
ttention to 31 8.6 8.5 8.7 8.8
onsult
eduled
31 7.8 7.6 8.7 7.5
of Surgery. 31 8.5 8.6 8.4 8.5
epartment. 31 8.1 8 8.1 8.3
h 31 8.7 8.7 8.9 8.8
tions 31 7.7 7.7 7.7 8
nurses. 31 7.5 7 8.7 8.3
31 7.8 7.9 7.6 7.8
logists. 30 7.6 7.6 7.5 8.3
30 7.8 7.8 7.6 8
omas. 31 7.7 7.7 7.9 8
ng in 31 7.7 7.6 7.7 8.3
30 7.8 7.5 8.1 8.7
26 7.6 7.6 7.3 –
onal 27 7.6 7.6 7.6 –
ational 24 7.5 7.4 7.8 –
astructure.
30 7.7 7.7 7.4 8.7
ees. 26 7.5 7.6 6.3 –
(continued on next page)
Table 4 (continued)
Quality Indicators Number
of
panelists
answering
Overall
score
Physicians'
score
Nurses'
score
Patients'
score
Outcome Quality Indicators
Outcome: Diagnosis and follow-up
75. Clostridium difficile infection should be evaluated in every flare
that presents as diarrhea.
24 7.6 7.9 6.5 –
76. In patients with a severe flare of colonic CD, rectal biopsies to rule
out Cytomegalovirus infection should be taken.
25 7.8 7.6 8.8 –
77. In patients with symptoms despite IBD treatment, activity should be
evaluated by colonoscopy or radiology to guide therapeutic decisions.
26 7.7 7.5 8.2 –
78. Patients should undergo surveillance for colorectal cancer unless the
procedures are contraindicated or if the patient refuses.
25 7.8 7.8 8.4 7
Outcome: Treatment
79. All IBD patients with any sign of tuberculosis should receive adequate
antituberculous therapy.
27 7.8 7.7 8.6 –
80. IBD patients under anti-TNF or immunosuppressive treatment should
be vaccinated against the flu.
20 7.8 8 8.5 5
Outcome: Treatment
81. IBD patients under triple immunosuppression (anti-TNF or cyclosporine
plus immunosuppressive drugs plus steroids) should receive prophylaxis
for Pneumocystis sp. infection.
25 7.8 7.7 8.6 –
82. Patients with CD should receive treatment to prevent recurrence
after surgery.
24 7.8 7.8 7.8 –
83. IBD patients should not have received steroids — even at doses lower
than 20 mg for more than 9 months during the last year.
24 7.7 7.7 – –
248 X. Calvet et al.following a standardized process, allowing the identification
of the QIs considered most relevant by major stakeholders
involved in the management of IBD, including health care
professionals and patients.
Three main aspects emerge as the basic requirements for
ICCUs from our study: i) continuity of care, with special
emphasis on the availability of on demand facilities, ii) the
central role of the specialist nurse – that is, a dedicated
nurse with special dedication and experience in IBD
management – and iii) the need for a multidisciplinary
approach including the participation of dedicated IBD
specialists, endoscopists, surgeons, radiologists and spe-
cialists in stoma management. The level of consensus on
these topics was very high for the majority of QIs. Many of
the outcome QIs refer to a safer use of available drugs,
prevention of disease complications, and the need for
adequate information and involvement of patients in their
own care. Finally, it is interesting that both health care
professionals and patients perceived research as essential
component of care in an ICCU.
QI ratings were quite similar between patients, nurses, and
medical doctors. Only two points that were not considered as
very important by nurses and physicians were regarded as a
priority by patients: having a protocol for their management
when admitted to the Emergency Department and having a
named, specific IBD specialist in charge of their care. The first
QI probably reflects the perception that non-specialized
urgent care is often sub-optimal in these difficult-to-treatpatients, and the second highlights the importance of
the personal relationship for adequate patient care. Being
managed by a team – even if the management is optimal –
causes insecurity in patients.
A few previous studies aimed at establishing QIs in some
aspects of IBD care have been published. Cassinotti et al. used
the UK IBD inpatient case audit tool, a set of QIs developed
from an audit in Oxford hospitals to compare inpatient care at
two European hospitals17. Van der Eijk et al.23 developed a set
of QIs to audit ICCUs in eight countries across Europe, although
the method for selecting the QIs was not described. Finally,
in 2009 the IBD Standards group published the first set of
UK national QIs for IBD patient care that includes many
structure and process QIs26. These QIs have been used in three
consecutive audits of UK ICCUs27–29.
The set of QIs established in the current study reproduce
some of the recommendations made by the IBD Standards
group in the UK Service QI26, but there are some notable
differences as well. Specifically, stakeholders in the
present consensus did not feel a number of previously
proposed QIs to be essential, in particular the availability
of a psychologist, a dietitian or a dedicated pharmacist or
reference rheumatologist, ophthalmologist, dermatolo-
gist or obstetrician, and the availability of joint gastroen-
terologist and surgeon consultations. On the other hand,
the role of the nurse and the need for a multidisciplinary
approach, though not strictly requiring a joint patient
visit, were identified as most relevant.
249Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsA major strength of the present study is the fact that the
Delphi system-based rating allowed the classification of the QIs
according to relevance. This makes it possible to increase or
reduce the number of QIs, retaining the most important ones
at all times. In addition, the QIs include not only structure
and process QIs, but also objective outcome QIs designed to
evaluate ICCU performance. Although QIs for IBD care will
probably change little from country to country, a limitation of
the present study is that the QIs were developed in the context
of the eminently public Spanish Healthcare System. As the
setup of ICCUs may be different in various countries, the
findings of this study may not be generalizable to other health
care systems due to differences in education, job profiles, and
other factors; for example, IBD nurses may not be available.
Nevertheless, most of the indicators are likely to be of help for
devising quality measurements even in health systems that
differ markedly from the Spanish one. In this regard, it is
interesting that many of the QIs selected in the present study
were considered as helpful aspects of IBD patient care in a
recent review by Kane40. Furthermore, the consensus selected
many (though not all) of the eight recently reported IBD
measurements of the PQRS – the performance measurements
program for the Centres for Medicare41 – as key QIs. It should
be also noted that very recently, Melmed et al.38 reported a set
of QIs for IBD management obtained using a Delphi method.
This group developed 10 QIs and 10 outcome measurements
for evaluating IBD management. Although with a different
wording, most of the standards were also included in the more
comprehensive list reported in the present study. The fact that
two similar studies in different settings reported similar QIs
supports the reliability of both sets of results.
A second limitation of the study may have been the
selection of the panelists. The panel attempted to represent a
wide range of ICCUs of different size and complexity around
Spain. The panelists were selected both by its scientific
background and clinical expertise in IBD and because they
worked or managed ICCUs. Gastroenterologists purposely
predominate because they are responsible for leading and
managing the ICCUs. Although we tried to include a wide
representation of all stakeholders – patients, nurses, gastro-
enterologists and surgeons – it could have been interesting to
include also other important specialties, namely radiologists,
general practitioners, psychologists, stoma therapists or
rheumatologists. This point should be taken into account for
future developments.
The QIs havemany uses and can be applied in different ways,
either using self-evaluation ormay be for determining the needs
for improvement of the different units or for the accreditation
of IBD units by scientific societies or administrations.
QI requirements could also favor further developments or
changes in the management of IBD patients; for example, the
results of the study might mean that not all hospitals can care
for IBD patients on their own, and a trade-off may appear in
less populated areas between geographical proximity and
availability of specific resources. In consequence, two or more
units may, for example, need to associate to create a surgical
team that complies with QI requirements.
Finally, QIs, like any another tool for treatment or
management of patients, are neither intrinsically useful
nor valuable. Their usefulness and applicability must be
demonstrated, and their costs and their effectiveness in
improving quality of care must be established.In conclusion, the present study identifies a set of key QIs
for evaluating and certifying ICCUs. Stakeholders participating
in the process rated the following characteristics of ICCU as
the most important: multidisciplinarity, continuity of care at
the different out and inpatient facilities, availability of on
demand assistance, and the strengthening of the safety of the
various therapeutic options.Authorship statement
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